These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36532196)

  • 1. Lower-dose psycholytic therapy - A neglected approach.
    Passie T; Guss J; Krähenmann R
    Front Psychiatry; 2022; 13():1020505. PubMed ID: 36532196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
    Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF
    Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.
    Zeifman RJ; Kettner H; Pagni BA; Mallard A; Roberts DE; Erritzoe D; Ross S; Carhart-Harris RL
    Sci Rep; 2023 Aug; 13(1):13645. PubMed ID: 37608057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute subjective effects in LSD- and MDMA-assisted psychotherapy.
    Schmid Y; Gasser P; Oehen P; Liechti ME
    J Psychopharmacol; 2021 Apr; 35(4):362-374. PubMed ID: 33853422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.
    Garcia-Romeu A; Richards WA
    Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).
    Nichols DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2331-2343. PubMed ID: 29461039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of consciousness and mystical-type experiences after acute LSD in humans.
    Liechti ME; Dolder PC; Schmid Y
    Psychopharmacology (Berl); 2017 May; 234(9-10):1499-1510. PubMed ID: 27714429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 13. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.
    Holze F; Vizeli P; Müller F; Ley L; Duerig R; Varghese N; Eckert A; Borgwardt S; Liechti ME
    Neuropsychopharmacology; 2020 Feb; 45(3):462-471. PubMed ID: 31733631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20
    Aday JS; Bloesch EK; Davoli CC
    J Psychoactive Drugs; 2019; 51(3):210-217. PubMed ID: 30836890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelic-Assisted Group Therapy: A Systematic Review.
    Trope A; Anderson BT; Hooker AR; Glick G; Stauffer C; Woolley JD
    J Psychoactive Drugs; 2019; 51(2):174-188. PubMed ID: 30950777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Psycholytic therapy: clinical psychotherapy with adjuvant LSD-25 and related substances].
    LEUNER H
    Z Psychother Med Psychol; 1963 Mar; 13():57-64. PubMed ID: 13929988
    [No Abstract]   [Full Text] [Related]  

  • 18. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects.
    Gasser P; Kirchner K; Passie T
    J Psychopharmacol; 2015 Jan; 29(1):57-68. PubMed ID: 25389218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Psycholytic interval therapy with LSD 25 or ambulant psychoanalytical therapy?].
    Derbolowsky U
    Z Psychother Med Psychol; 1966 Jan; 16(1):33-8. PubMed ID: 5911900
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin.
    Varker T; Watson L; Gibson K; Forbes D; O'Donnell ML
    J Psychoactive Drugs; 2021; 53(1):85-95. PubMed ID: 32931403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.